An Integrated MS Proteomics Platform from Biomarker Discovery to Customized Assay Panelsheld

• State-of-the-art mass spectrometry platform for unbiased biomarker discovery and development of customized assay panels across various biological specimen
• Sub-protein resolution allows quantification of proteoforms such as post-translational modifications, isoforms, and mutations
• Discovery of biomarker signatures through quantitative profiling of paired CSF-plasma samples from an Alzheimer’s Disease cohort

Using A Dual Proteomics And Multiplexed IF Approach For The Detection Of Biomarkers Predictive For Response To ICI-Therapy

• Identification of over 70 proteins differentially regulated in melanoma patients responding to therapy
• Several immune phenotypes, including T cell subsets and M1 TAMs, significantly increased in responders